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ABSTRACT 
Background: Aromatase inhibitors improve disease-free survival compared with tamoxifen in 
postmenopausal women with hormone-receptor-positive breast cancer. The Tamoxifen and 
Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy versus 
sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically 
significant difference between treatment arms. A robust translational program was established to 
investigate predictive biomarkers. 
Methods: A tissue microarray was retrospectively constructed using a subset of patient tissues 
(n=4631) from the TEAM trial (n=9766). Immunohistochemistry was performed for biomarkers, 
classed into three groups: MAPK pathway, NF-kappa B pathway, and ER phosphorylation. 
Expression was analysed for association with relapse-free survival (RFS) at 2.5 and 10 years and 
treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were 
two-sided.  
Results: On univariate analysis, ER
167
 (HR 0.71 95% CI 0.59-0.85, p<0.001), IKKα (HR 0.74 
95% CI 0.60-0.92, p=0.005), Raf-1
338
 (HR 0.64 95% CI 0.52-0.80, p<0.001), and p44/42 
MAPK
202/204 
(HR 0.77 95% CI 0.64-0.92, p=0.004) were statistically significantly associated 
with improved RFS at 10 years in patients receiving sequential therapy. Associations were 
strengthened when IKKα, Raf-1338 and ER167 were combined into a cumulative prognostic score 
(HR 0.64 95% CI 0.52-0.77, p<0.001). Patients with an all negative IKKα, Raf-1338 and ER167 
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score, favoured exemestane monotherapy (OR 0.56 95% CI 0.35-0.90). On multivariate analysis, 
the IKKα, Raf-1338 and ER167 score (p=0.001) was an independent prognostic factor for RFS at 
10 years in patients receiving sequential therapy.  
Conclusions: The IKKα, Raf-1338 and ER167 score is an independent predictive biomarker for 
lower recurrence on sequential therapy. Negative expression may further offer predictive value 
for exemestane monotherapy. 
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INTRODUCTION 
Treatment of breast cancer has evolved and tamoxifen is no longer the only adjuvant 
endocrine therapy available for postmenopausal women with estrogen receptor-positive (ER-
positive) (1). Third generation aromatase inhibitors (AIs, anastrozole, exemestane and letrozole), 
which induce suppression of circulating estrogens increase disease free survival in 
postmenopausal hormone receptor-positive breast cancer. Treatment with AIs for 5 years 
improved disease-free survival compared with tamoxifen for 5 years (2, 3). In the Intergroup 
Exemestane Study (IES), patients who switched to exemestane after 2–3 years of tamoxifen had 
statistically significantly improved disease-free survival and overall survival compared to those 
remaining on tamoxifen (4). Therefore AIs alone or in sequence with tamoxifen are now 
recommended as adjuvant therapy for postmenopausal breast cancer (5).  
Although currently there are established recurrence score such as Oncotype DX, Pam50 
and the combined endocrine score (6-8), there are no biomarkers available to predict which 
patients will gain maximum benefit from each treatment strategy. NICE guidelines suggest that 
decisions should be based on discussions between the patient and oncologist, focussing on 
benefits and risks of each option, risk of recurrence and previous tamoxifen use (5). Clearly 
biomarkers are required to aid clinician decision-making. The Tamoxifen and Exemestane 
Adjuvant Multinational (TEAM) trial compared exemestane monotherapy versus sequential 
therapy of tamoxifen followed by exemestane for a total of five years (9), providing an ideal 
cohort to retrospectively investigate biomarkers that predict patients most likely to benefit from 
either exemestane monotherapy or tamoxifen followed by exemestane. The TEAM trial did not 
show a specific benefit of one therapeutic regimen over the other, both after 5 and 10 years (9). 
The current study investigated potential predictive biomarkers for endocrine therapy, 
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classed into three groups; MAPK pathway (10), NF-kappaB pathway (11), and phosphorylation 
of ER (12, 13) that have been previously reported as prognostic in postmenopausal hormone 
receptor-positive (HRec-positive) breast cancer.  
  
 
PATIENTS AND METHODS 
Patients and study design 
The TEAM trial is a multinational, randomized, open-label, phase III trial in 
postmenopausal women with HRec-positive early breast cancer (Trial registration number 
NCT00032136) (9). Women randomly received either exemestane (25mg) once daily for five 
years or tamoxifen (20mg) once daily for 2.5 years followed by exemestane for a total of five 
years. The study complied with the Declaration of Helsinki, individual ethics committee 
guidelines, and the International Conference of Harmonization and Good Clinical Practice 
Guidelines. All patients provided informed consent. Further details are in the Supplementary 
Methods.  
From the 9766 patients from the TEAM trial, only five of the nine eligible TEAM 
countries (n=6210) agreed to provided tumour samples. 4781 patients had available tissue from 
surgical resections for tissue microarray (TMA) construction with linked clinicopathological data 
(14). Of these 4631 patient samples were eligible for biomarker staining (Figure 1). 86 patients 
were ER-negative, and 101 had cores missing for all stains and were therefore excluded leaving 
4444 eligible patients for analysis. 
 
Immunohistochemistry  
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Immunohistochemical expression of IKKα, p65536, N-Ras, Raf-1338, p44/42 MAPK202/204, 
ER
118
, and ER
167
 was conducted on a TMA using the Benchmark XT (Ventana Medical Systems, 
Roche, Tucson, Arizona) automated staining platform (14). Stained TMA sections were scanned 
using a Hamamatsu NanoZoomer at x20 magnification and visualized on Slidepath Digital 
Image Hub (Leica Biosystems, Newcastle, UK). If cores were missing or contained less than 
10% tumour tissue they were excluded from analysis (Figure 1). Assessment of cytoplasmic 
IKKα expression was performed by a single examiner (LB) blinded to clinical data at x20 
magnification (total magnification x400) using the weighted histoscore and 10% double scored 
by JE. The interclass coefficient (ICC) was 0.95. All other proteins were assessed using an 
automated computer algorithm of the weighted histoscore for nuclear expression, except N-Ras 
and Raf-1
338
 were cytoplasmic expression was assessed (Leica Biosystems). 10% of tumours 
were manually scored by a single examiner (JE) blinded to the clinical data. The ICC for each 
biomarker was ER
118
 0.79, ER
167
 0.99, p65
536
 0.98, N-Ras 0.96, Raf-1
338 
0.92, and p44/42 
MAPK
202/204 
0.99.  Further details are in the Supplementary Methods.  
 
Outcomes 
The co-primary outcomes were relapse-free survival at 2.5 years (RFS; defined as time to 
earliest documentation of disease relapse or death due to breast cancer) and RFS at 10 years. 
Secondary outcomes included biomarker associations with clinicopathological factors and 
treatment regimen. 
 
Statistical Analysis 
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The prospectively powered outcome analysis for this study compared high expression 
(approximately 50%) and low expression (approximately 50%). By using a two-sided α=0.05 
analysis and assuming a hazard ratio (HR) of 1.2 and a low expression prevalence of 50%, a 
sample size of >1000 patients gave >90% power to detect a treatment-biomarker interaction. 
Therefore the 4646 eligible samples from this trial population would be adequate to identify 
treatment-biomarker interactions, with at least 90% power.  
Histograms were assessed for each protein and IKKα, ER167, Raf-1338 and p44/42 MAPK202/204 
histograms determined that negative and positive expression was the appropriate threshold. 
p65
536
, N-Ras, and ER
118
 were analysed using ROC analysis in a discovery cohort and validated 
using the current cohort, the following thresholds were determined for each protein: 25 for 
p65
536
, 100 for N-Ras, and 110 for ER
118
. SPSS (version 22, IBM, Armonk, New York) was used 
for statistical analysis unless otherwise stated. Pearson’s χ2 test assessed associations between 
biomarkers, treatments, and clinicopathological features. Odds ratios compared biomarker 
associations with treatment regimens using tamoxifen followed by exemestane as the control 
group and exemestane monotherapy as the experimental group and were displayed as Forrest 
Plots (showing I
2
 for heterogeneity and Z-score for overall effect) with each biomarker as a 
separate study (RevMan 5.3, Cochrane, London, UK). Kaplan-Meier and log-rank analysis 
compared RFS at both time points. HRs and CIs were calculated from univariate cox regression 
survival analysis. Multivariate cox regression survival analysis using a backward conditional 
elimination model and a statistical significance threshold of p<0.01 was performed to identify 
independent prognostic biomarkers. The study conformed to the REMARK guidelines (15) and 
statistical significance was set as p<0.01. All statistical tests were two-sided.  
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RESULTS 
Study group 
Of the 9766 patients from the TEAM trial treated for HRec-positive early breast cancer, 
4444 patients were included in this study (Figure 1). Patient characteristics are shown in Table 
1. In brief, 100.0% were ER-positive, 68.3% PR-positive, 39.1% HER2-positive, and 67.7% 60 
years or older at surgery. 51.4% had grade II disease and 30.8% had grade III/IV disease. 57.6% 
were node positive and 8.9% had lymphovascular invasion. 2240 patients received exemestane 
monotherapy (50.4%) and 2204 patients received tamoxifen followed by exemestane therapy 
(49.6%). The median follow-up of survivors was 8.8 years (range 1.0-13.9 years) with 1054 
recurrences and 1161 deaths. When compared to the full TEAM trial, the characteristics of the 
patients were similar. However, the patients in the present study appeared to have higher grade, 
larger tumors and more nodal involvement. Nevertheless, the present cohort was a fair 
representation of the full TEAM trial.  
 
Associations between biomarkers and relapse-free survival at 2.5 and 10 years. 
Univariate analysis of biomarker associations with relapse-free survival (RFS) at 2.5 and 
10 years are shown in Table 2. ER
118
 phosphorylation was not associated with RFS at either time 
point. However, ER
167
 phosphorylation statistically significantly associated with improved RFS 
at both 2.5 years (HR 0.73 95% CI 0.59-0.92, p=0.007) and 10 years (HR 0.82 95% CI 0.71-
0.94, p=0.004). For the NF-kappaB pathway, p65
536
 phosphorylation did not associate with RFS 
at either time point. However, positive IKKα expression statistically significantly associated 
with improved RFS at 10 years (HR 0.80 95% CI 0.69-0.93, p=0.003). For the MAPK pathway, 
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N-Ras did not associate with RFS at either time point. However, phosphorylation of Raf-1
338
 
(HR 0.62 95% CI 0.48-0.81, p<0.001) and p44/42 MAPK
202/204
 (HR 0.70 95% CI 0.56-0.88, 
p=0.002) strongly associated with improved RFS at 2.5 years. Both Raf-1
338
 (HR 0.69 95% CI 
0.59-0.80, p<0.001) and p44/42 MAPK
202/204 
(HR 0.76 95% CI 0.66-0.86, p<0.001) associations 
with improved RFS were strengthened at 10 years.  
A cumulative prognostic score of the NF-kappa B and MAPK pathways was examined 
(IKKα and Raf-1338). Patients with positive IKKα expression and phosphorylation of Raf-1338 
were classified as both-positive, patients with positive IKKα expression or Raf-1338 
phosphorylation as one-positive and patients with negative IKKα and Raf-1338 expression as 
both-negative. A both-positive IKKα and Raf-1338 score strengthened the association with 
improved RFS at 10 years (HR 0.78 95% CI 0.71-0.87, p<0.001) and 2.5 years (HR 0.77 95% CI 
0.65-0.91, p=0.005) as shown in Table 2. ER
167
 phosphorylation was added to the cumulative 
prognostic score. Patients with negative IKKα, Raf-1338 and ER167 were defined as all-negative, 
patients with positive expression of one or two from IKKα, Raf-1338 or ER167 as one/two-positive 
and patients with positive IKKα, Raf-1338 and ER167 as all-positive. Patients with an all-positive 
IKKα, Raf-1338 and ER167 score strengthened associations with improved RFS at 10 years (HR 
0.73 95% CI 0.64-0.85, p<0.001). 
 
Associations between biomarkers, treatment regimens, and relapse-free survival at 2.5 and 
10 years. 
Univariate analysis was performed for treatment by biomarker interaction and its 
associations with RFS at 2.5 and 10 years as shown in Table 3. Patients receiving tamoxifen 
followed by exemestane therapy had a statistically significant improvement in RFS at 10 years 
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with phosphorylation of ER
167
 (HR 0.71 95% CI 0.59-0.85, p<0.001). This was not observed in 
patients receiving exemestane monotherapy (HR 0.96 95% CI 0.79-1.16, p=0.66). Similarly, 
patients receiving tamoxifen followed by exemestane therapy had a statistically significant 
improvement in RFS at 10 years with positive IKKα expression (HR 0.74 95% CI 0.60-0.92, 
p=0.005) (Figure 2A). This was not observed in patients receiving exemestane monotherapy 
(HR 0.86 95% CI 0.69-1.07, p=0.17) (Figure 2A). Furthermore, patients receiving tamoxifen 
followed by exemestane therapy had improved RFS at 2.5 years when Raf-1
338
 (HR 0.58 95% CI 
0.41-0.83, p=0.003) or p44/42 MAPK
202/202 
(HR 0.66 95% CI 0.49-0.89, p=0.006) is 
phosphorylated, which was not observed in patients receiving exemestane monotherapy (Raf-
1
338
: HR 0.68 95% CI 0.47-0.98, p=0.04 or p44/42 MAPK
202/204
: HR 0.77 95% CI 0.56-1.06, 
p=0.11). Similarly, patients receiving tamoxifen followed by exemestane therapy had a 
statistically significant improvement in RFS at 10 years for both Raf-1338 (HR 0.64 95% CI 
0.52-0.80, p<0.001) and p44/42 MAPK
202/204 
expression (HR 0.77 95% CI 0.64-0.92, p=0.004) 
as shown in Table 3. However, the different pattern between treatment regimens for Raf-1
338
 and 
p44/42 MAPK
202/204 
was lost by 10 years with patients receiving exemestane monotherapy also 
having a statistically significant improvement in RFS (Raf-1
338
: HR 0.74 95% CI 0.60-0.91, 
p=0.004 or p44/42 MAPK
202/204
: HR 0.75 95% CI 0.62-0.90, p=0.002). Furthermore, no 
biomarker by treatment associations (Figure 3) were observed at 10 years for either Raf-1
338 
(OR 
0.97 95% CI 0.83-1.12) or p44/42 MAPK
202/204
 (OR 0.96 95% CI 0.83-1.11). 
For the IKKα and Raf-1338 score, patients with a both-positive score receiving tamoxifen 
followed by exemestane therapy also showed a statistically significant improvement in RFS at 
10 years (HR 0.73 95% CI 0.63-0.84, p<0.001) (Figure 2B). However, when assessing 
biomarker by treatment interactions, patients with negative IKKα expression receiving tamoxifen 
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followed by exemestane therapy had shorter RFS than patients receiving exemestane 
monotherapy, although this did not reach statistical significance (HR 1.24 95% CI 0.1.02-1.51, 
p=0.03) (Figure 4A). Furthermore, patients with a both-negative IKKα and Raf-1338 score do 
statistically significantly worse on tamoxifen followed by exemestane compared to exemestane 
monotherapy (HR 1.35 95% CI 1.08-1.68, p=0.009) (Figure 4B). These results were then 
confirmed with forest plots for biomarker by treatment interactions (Figure 3) with both 
negative IKKα expression (OR 0.79 95% CI 0.63-0.99) and a both-negative IKKα and Raf-1338 
score (OR 0.72 95% CI 0.55-0.93) favouring exemestane monotherapy. 
To assess how interactions between all three pathways associate with treatment regimen, 
the IKKα, Raf-1338 and ER167 score was assessed (Table 3). Patients receiving tamoxifen 
followed by exemestane therapy with an all-positive IKKα, Raf-1338 and ER167 score had 
statistically significantly improved survival at 10 years (HR 0.64 95% CI 0.52-0.77, p<0.001) 
(Figure 2C). This was not observed for exemestane monotherapy (HR 0.75 95% CI 0.70-1.04, 
p=0.27) (Figure 2C). When assessing biomarker by treatment associations, patients with an all-
negative IKKα, Raf-1338 and ER167 score favoured exemestane monotherapy (OR 0.56 95% CI 
0.35-0.90, Figure 3). 
 
Associations between biomarkers and common clinicopathological characteristics 
Since IKKα, Raf-1338, p44/42 MAPK202/204, and ER167 associated with RFS and patient 
treatments, associations with common clinicopathological factors were assessed 
(Supplementary Table 1). ER
167
 phosphorylation statistically significantly associated with 
lower grade (p=0.001), whereas IKKα statistically significantly associated with lower nodal 
status (p<0.001) and Ki67 index (p=0.008). Raf-1
338
 statistically significantly associated with 
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lower grade (p<0.001), lower nodal status (p<0.001), smaller size (p<0.001), increased PR status 
(p<0.001), and decreased Ki67 index (p=0.004). Whereas p44/42 MAPK
202/204 statistically 
significantly associated with lower age (p=0.001), lower grade (p<0.001), lower nodal status 
(p<0.001), and decreased lymphovascular invasion (p<0.001). 
 
Multivariate analysis of biomarkers, treatment regimen, clinicopathological characteristics 
and relapse-free survival at 2.5 and 10 years 
IKKα, Raf-1338, p44/42 MAPK202/204, and ER167 were then taken forward into 
multivariate analysis along with age, grade, nodal status, size, PR status and Ki67 index (Table 
4). In the full cohort, multivariate survival analysis for RFS at 2.5 years (n=2827) showed age 
(p<0.001), nodal status (p<0.001), size (p=0.002), and Ki67 index (p<0.001) were independent 
prognostic factors. Whereas multivariate survival analysis for RFS at 10 years (n=1963) 
demonstrated that age (p<0.001), size (p<0.001), HER2 status (p=0.001), and Ki67 index 
(p=0.006) were independent prognostic factors. Patients were then split by treatment regimen 
and multivariate analysis performed for each cohort (Table 4). For patients receiving exemestane 
monotherapy, RFS at 2.5 years (n=1429) showed age (p=0.004), nodal status (p=0.001), size 
(p=0.008), and Ki67 index (p=0.001) were independently prognostic. Similarly, RFS at 10 years 
(n=980) showed age (p<0.001), size (p<0.001), and PR status (p=0.001) were independent 
prognostic factors. Whereas for patients receiving tamoxifen followed by exemestane therapy, 
RFS at 2.5 years (n=1398) showed age (p<0.001), nodal status (p=0.008), and Ki67 index 
(p=0.001) were independently prognostic. However, RFS at 10 years (n=983) showed age 
(p=0.001), size (p=0.001), ER
167
 phosphorylation (p=0.002), the IKKα and Raf-1338 score 
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(p=0.008), and the IKKα, Raf-1338 and ER167 score (p=0.001) were independent prognostic 
factors. 
 
 
DISCUSSION 
The current study demonstrated that an all-positive IKKα, Raf-1338 and ER167 score is an 
independent predictor of response to sequential therapy of tamoxifen followed by exemestane. 
Furthermore, an all-negative IKKα, Raf-1338 and ER167 score is predictive for response to 
exemestane monotherapy. Utilizing IKKα, Raf-1338 and ER167 could ensure the most effective 
endocrine therapy regimen is administered to patients. 
Bennett et. al. reported that high IKKα expression was associated with shorter RFS in 
ER-positive tamoxifen-treated patients (11). In contrast, the present study reports that IKKα 
expression is associated with improved RFS in ER-positive patients receiving tamoxifen 
followed by exemestane. This discordance may be explained by differences in the thresholds 
employed; Bennett et al. (11) employed the median whereas the present study used positive and 
negative, making direct comparisons difficult. Nevertheless, the data suggests that the addition of 
exemestane changes the prognostic power of IKKα. During long-term tamoxifen treatment (5 
years), blockade of ER lead to higher free estrogen levels promoting the formation of an 
ER/IKKα complex to enhance transcriptional activity, which results in reduced RFS after 2 years 
as observed by Bennett et al. (16). However, if exemestane is administered following short-term 
tamoxifen treatment (2.5 years), estrogen levels fall and the ER/IKKα complex is released to 
phosphorylate ER
 
in a ligand-independent manner resulting in improved RFS as observed in the 
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current study (16). This is not observed in the exemestane monotherapy patients, as the initial 
formation of the ER/IKKα complex is required to improve RFS. 
Of interest, McGlynn et al. reported that high Raf-1
338
 was associated with shorter RFS 
on tamoxifen (10). However, in the present study, patients that received tamoxifen for 2.5 years 
showed an increase in RFS, which was also observed for both treatments at 10 years. Again, this 
discordance may be due to differences in the thresholds used for the two studies; McGlynn et al. 
used the upper quartile whereas the present study assessed negative or positive, making direct 
comparisons difficult. Therefore it would appear that depending on the threshold employed 
slightly different results may be obtained. Of note, these studies are retrospective and may be 
subject to selection biases. However, other studies observed that when estrogen production is 
ablated, p44/42 MAPK phosphorylates ER
167
 to induce transcription of alternative ER-dependent 
genes (17). When tamoxifen is administered long-term, the partial agonist activity of tamoxifen 
causes activation of ER, which in turn activates Raf-1 causing increased tumor growth as 
observed by McGlynn et al. However, when estrogen production is ablated by exemestane alone 
or following short-term tamoxifen treatment, ER-independent phosphorylation of Raf-1
338
 can 
promote p44/42 MAPK to phosphorylate ER
167
 resulting in up-regulation of alternative gene 
transcription, conveying good prognosis to the patients as observed in the present study (18).   
The cumulative prognostic score demonstrated that patients with both-positive IKKα and 
Raf-1
338
 expression had a better prognosis on tamoxifen followed by exemestane therapy 
compared to patients with negative expression of one of the biomarkers, suggesting it could be 
used as a predictive biomarker for patients receiving sequential therapy. Previous studies have 
demonstrated that IKKα can phosphorylate p44/42 MAPK suggesting IKK alpha may work with 
Raf-1 to enhance ER
167 
phosphorylation (19). To assess this ER
167
 phosphorylation was added to 
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the cumulative prognostic score. Associations with improved RFS were enhanced in patients 
receiving tamoxifen followed by exemestane therapy, suggesting IKKα and Raf-1 independently 
phosphorylate ER
167
. This was confirmed in exemestane monotherapy patients as no 
improvement in RFS was observed suggesting the addition of the primed ER/IKK alpha complex 
enhances the beneficial effects of ER
167
. This data suggest that an all-positive IKKα, Raf-1338 
and ER
167
 score could be utilized as a predictive biomarker for lower recurrence in patients 
receiving tamoxifen followed by exemestane therapy.   
Conversely, patients with an all-negative IKKα, Raf-1338 and ER167 score favored 
exemestane monotherapy with statistically significantly improved RFS. This suggests that when 
IKKα and Raf-1 are not present, the build-up of free estrogens during tamoxifen treatment 
promote tumour progression by competing for ER and exemestane is unable to stop this 
detrimental effect without IKKα and Raf-1. However, in the exemestane monotherapy patients, 
estrogens never activate ER, inhibiting tumour recurrence. These results suggest that an all-
negative IKKα, Raf-1338 and ER167 score might be utilized to select patients for exemestane 
monotherapy.  
The present study also assesses HER2 status and uses 10-year follow-up, which was not 
available when the trial was originally reported. The main limitation of this study is its 
retrospective nature and that of the 9766 patients included in the TEAM trial, only 4444 patients 
had tissue available for use in this study. Furthermore, of the 4444 patient in the present cohort, 
only 2827 were included in the multivariate analysis due to missing data. However, even with 
these limitations the IKKα, Raf-1338 and ER167 score was demonstrated to predict recurrence in 
postmenopausal breast cancer patients treated with endocrine therapy. Patients with an all-
positive score should be treated with sequential therapy of tamoxifen followed by exemestane, 
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whereas patients with an all-negative score should be treated with exemestane monotherapy. As 
the results describe predictive biomarkers for response to different endocrine therapy regimens 
and not prognostic biomarkers of general recurrence, it is not clear how the present work may be 
incorporated into existing recurrence models.   
In conclusion, although validation is warranted in other translational studies of 
comparative clinical trial patients, utilizing the IKKα, Raf-1338 and ER167 score could ensure the 
most effective endocrine therapy regimen is administered to patients most likely to gain 
maximum benefit. Furthermore, this cumulative score is readily translatable to the clinical 
scenario as it utilizes techniques already in daily use and is scored as negative or positive which 
is easily automated within this setting. These observations may only apply to a minority of 
patients, however applying the correct treatment at the correct time is a key goal in personalised 
medicine and is likely to improve the outcome of patients with breast cancer.   
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FIGURE LEGENDS 
Figure 1. Flow diagram showing criteria for exclusion of patients from study.  Tissue Micro 
Array = TMA,  Estrogen receptor = ER, Inhibitory Kappa Kinase = IKK, Mitogen Activated 
Protein Kinase = MAPK 
Figure 2. IKKα, Raf-1338 and ER167 score as a prognostic biomarker for recurrence in 
patients receiving tamoxifen followed by exemestane therapy. (A) Kaplan Meier showing 
RFS at 10 years for IKKα in patients receiving either exemestane monotherapy or tamoxifen 
followed by exemestane therapy. (B) Kaplan Meier showing RFS at 10 years for the IKKα and 
Raf-1
338
 score in patients receiving either exemestane monotherapy or tamoxifen followed by 
exemestane therapy (C) Kaplan Meier showing RFS at 10 years for the IKKα, Raf-1338 and ER167 
score in patients receiving either exemestane monotherapy or tamoxifen followed by exemestane 
therapy. All statistical tests were two-sided. HR=hazard ration; CI=confidence interval. 
Figure 3. Biomarker associations with treatment regimen. Forest plot for RFS at 10 years, 
showing whether a biomarker favours exemestane monotherapy (experimental group) or 
tamoxifen followed by exemestane therapy (control group), in postmenopausal early breast 
cancer patients. All statistical tests were two-sided and error bars represent 95% CI. 
CI=confidence interval; df=degrees of freedom; I
2
=heterogeneity score; Z=z-score; =individual 
odds ratio =combined odds ratio. 
Figure 4. Both negative IKKα and Raf-1338 score as a predictive biomarker for exemestane 
monotherapy. (A) Kaplan Meier showing RFS at 10 years for treatment regimen in patients 
with either negative or positive expression of IKKα. (B) Kaplan Meier showing RFS at 10 years 
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for treatment regimen in patients with either a both negative or both positive IKKα and Raf-1338 
score. All statistical tests were two-sided. HR=hazard ration; CI=confidence interval. 
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Table 1. Baseline characteristics of patients 
 
Characteristics 
TEAM study 
(n=9766) 
Pathology 
substudy 
(n=6120) 
Biomarker substudy 
(n=4444) 
No. of Patients 
(%) 
No. of 
Patients (%) 
No. of 
Patients (%) 
Univariate Analysis 
RFS at 2.5yrs RFS at 10yrs 
No. of 
Events 
HR (95% CI) p value
*
 
No. of 
Events 
HR (95% CI) p value
*
 
Age  
<50 
50-59 
60-69 
>70 
 
331 (3.2) 
3017 (30.9) 
3731 (38.4) 
2687 (27.5) 
 
211 (3.4) 
1874 (30.6) 
2373 (38.8) 
1662 (27.2) 
 
115 (2.6) 
1322 (29.7) 
1703 (38.3) 
1304 (29.4) 
 
7 
88 
129 
146 
1.31 (1.16-1.49) <0.001  
22 
240 
357 
435 
1.42 (1.32-1.53) <0.001 
Grade  
1 
2 
3-4 
Unknown 
 
1677 (17.2) 
4795 (49.1) 
2438 (25.0) 
856 (8.7) 
 
616 (10.1) 
3166 (51.8) 
1835 (30.0) 
503 (8.1) 
 
520 (11.7) 
2284 (51.4) 
1369 (30.8) 
271 (6.1) 
 
33 
168 
150 
19 
1.27 (1.11-1.45) 0.001  
91 
529 
371 
63 
1.15 (1.07-1.24) <0.001 
Nodal Status  
absent 
present 
unknown 
 
5113 (52.4) 
4585 (46.9) 
68 (0.7) 
 
2604 (42.5) 
3494 (57.1) 
22 (0.4) 
 
1884 (42.4) 
2560 (57.6) 
0 (0) 
 
117 
253 
- 
1.62 (1.30-2.02) <0.001  
353 
701 
- 
1.52 (1.34-1.73) <0.001 
Size  
<20mm 
>20mm 
Unknown 
 
5697 (58.3) 
4047 (41.4) 
22 (0.3) 
 
3028 (49.4) 
3027 (49.4) 
65 (1.2) 
 
2139 (48.1) 
2172 (48.9) 
133 (3.0) 
 
124 
237 
- 
1.95 (1.56-2.42) <0.001  
363 
662 
- 
1.97 (1.74-2.24) <0.001 
PR status  
absent 
present 
not performed 
 
1724 (17.7) 
7301 (74.8) 
741 (7.5) 
 
1070 (17.5) 
4378 (71.5) 
672 (11.0) 
 
826 (18.6) 
3034 (68.3) 
584 (13.1) 
 
101 
224 
45 
1.14 (0.99-1.31) <0.001  
261 
658 
135 
1.12 (1.03-1.21) <0.001 
HER2 Status 
absent 
present 
not performed 
 
- 
- 
- 
 
2796 (45.7) 
1908 (31.2) 
1416 (23.1) 
 
1776 (39.7) 
1738 (39.1) 
940 (21.2) 
 
134 
159 
- 
1.21 (0.96-1.52) 0.11  
377 
469 
- 
1.22 (1.06-1.40) 0.005 
Ki67 status  
low (<15) 
high (>15) 
unknown 
 
- 
- 
- 
 
2308 (37.7) 
1064 (17.4) 
2748 (44.9) 
 
2277 (51.2) 
1027 (23.1) 
1140 (25.7) 
 
156 
127 
- 
1.87 (1.48-2.36) <0.001  
489 
305 
- 
1.48 (1.29-1.71) <0.001 
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Treatment  
exemestane 
tamoxifen then 
exemestane 
 
4898 (50.2) 
4868 (49.8) 
 
3075 (50.2) 
3045 (49.8) 
 
2240 (50.4) 
2204 (49.6) 
 
1169 
1201 
1.22 (1.00-1.50) 0.05  
523 
531 
1.05 (0.93-1.18) 0.45 
Lymphovascular Invasion  
no 
yes 
unknown 
 
- 
- 
- 
 
3845 (62.8) 
403 (6.6) 
1872 (30.6) 
 
3727 (83.9) 
394 (8.9) 
323 (7.2) 
 
299 
40 
- 
0.78 (0.56-1.08) 0.13  
881 
101 
- 
0.90 (0.73-1.10) 0.31 
 
RFS = relapse-free survival; HR = Hazard Ratio; CI = Confidence interval; -- = data not available 
*
Kaplan-Meier and log-rank analysis compared RFS at both 
time points. HRs and CIs were calculated from univariate cox regression survival analysis.  All statistical tests were two-sided. 
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Table 2. Univariate analysis of associations between biomarkers and RFS at 2.5 and 10 years in postmenopausal HRec-positive 
early breast cancer patients. 
Biomarkers 
Number of 
Patients 
RFS 2.5 
events 
RFS 10 
events 
Relapse-free survival at 2.5yrs Relapse-free survival at 10yrs 
HR (95% CI) p value
*
 HR (95% CI) p value
*
 
phospho ER
118 
(n=4218) 
low expression (<110 WHS units) 
high expression (>110 WHS units) 
 
3157 
1061 
 
266 
86 
 
777 
218 
0.96 (0.75-1.22) 0.73 0.83 (0.71-0.96) 0.01 
phospho ER
167 
(n=4133) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
1150 
2983 
 
115 
222 
 
304 
670 
0.73 (0.59-0.92) 0.007 0.82 (0.71-0.94) 0.004 
IKK alpha (n=3024) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
1579 
1445 
 
144 
114 
 
400 
298 
0.86 (0.68-1.11) 
 
0.24 
 
 
0.80 (0.69-0.93) 
 
0.003 
 
 
phospho p65
536 
(n=4053) 
low expression (<25 WHS units) 
high expression (>25 WHS units) 
 
857 
3196 
 
70 
271 
 
219 
739 
1.03 (0.79-1.34) 
 
0.81 
 
 
0.89 (0.77-1.04) 
 
0.15 
 
 
N-Ras (n=4039) 
low expression (<100 WHS units) 
high expression (>100 WHS units) 
 
3952 
87 
 
337 
5 
 
929 
28 
0.66 (0.28-1.61) 
 
0.36 
 
 
1.36 (0.94-1.96) 
 
0.11 
 
 
Raf-1
338 
(n=4030) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
2797 
1233 
 
266 
74 
 
728 
224 
0.62 (0.48-0.81) <0.001 0.69 (0.59-0.80) <0.001 
p44/42 MAPK
202/204 
(n=4055) 
negative expression (0 WHS units) 
positive expression (>0 WHS units) 
 
2249 
1806 
 
217 
125 
 
590 
369 
0.70 (0.56-0.88) 0.002 0.76 (0.66-0.86) <0.001 
IKK alpha and Raf-1
338
 (n=2980) 
both negative 
one positive 
both positive 
 
1154 
1158 
668 
 
115 
102 
37 
 
316 
254 
116 
0.77 (0.65-0.91) 0.005 0.78 (0.71-0.87) <0.001 
IKK alpha, Raf-1
338
 and ER
167
 
(n=2904) 
all negative 
one or two positive 
all positive 
 
339 
2037 
528 
 
37 
178 
29 
 
104 
471 
93 
0.71 (0.56-0.89) 0.01 0.73 (0.64-0.85) <0.001 
RFS = relapse-free survival; HR = Hazard Ratio; CI = Confidence interval; WHS = weighted histoscore .
*
Kaplan-Meier and log-rank analysis compared RFS at 
both time points. HRs and CIs were calculated from univariate cox regression survival analysis.  All statistical tests were two-sided.. 
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Table 3. Univariate analysis of associations between biomarkers, treatment regimen, and RFS at 2.5 and 10 years in 
postmenopausal HRec positive early breast cancer patients 
 
 
RFS = relapse-free survival; HR = Hazard Ratio; CI = Confidence interval. 
*
Kaplan-Meier and log-rank analysis compared RFS at both time points. HRs and CIs 
were calculated from univariate cox regression survival analysis.  All statistical tests were two-sided. 
 
 
  
Exemestane Tamoxifen then exemestane 
Biomarkers 
Number of 
Patients 
RFS 2.5 
events 
RFS 10 
events 
Relapse-free survival at 2.5yrs Relapse-free survival at 10yrs Number 
of Patients 
RFS 2.5 
events 
RFS 10 
events 
Relapse-free survival at 2.5yrs Relapse-free survival at 10yrs 
HR (95% CI)  p value* HR (95% CI)  p value* HR (95% CI)  p value* HR (95% CI)  p value* 
ER118  
low expression  
high expression  
 
1587 
550 
 
112 
47 
 
380 
115 
1.22 (0.87-1.71) 0.26 0.87 (0.71-1.07) 0.19  
1570 
511 
 
154 
39 
 
397 
103 
0.77 (0.54-1.09) 0.14 0.78 (0.63-0.97) 0.03 
ER167  
negative expression  
positive expression  
 
594 
1491 
 
55 
96 
 
141 
342 
0.68 (0.49-0.95) 0.02 0.96 (0.79-1.16) 0.66  
556 
1492 
 
60 
126 
 
163 
342 
0.77 (0.57-1.05) 0.10 0.71 (0.59-0.85) <0.001 
IKK alpha  
negative expression  
positive expression  
 
791 
744 
 
65 
49 
 
183 
150 
0.80 (0.55-1.16) 0.23 0.86 (0.69-1.07) 0.17  
788 
701 
 
79 
65 
 
217 
148 
0.93 (0.67-1.29) 0.66 0.74 (0.60-0.92) 0.005 
p65536  
low expression  
high expression  
 
422 
1623 
 
28 
127 
 
112 
362 
1.19  (0.79-1.79) 0.41 0.83 (0.67-1.02) 0.08  
453 
1573 
 
42 
144 
 
107 
377 
0.93 (0.69-1.32) 0.69 0.97 (0.78-1.20) 0.76 
N-Ras  
low expression  
high expression  
 
1991 
48 
 
154 
1 
 
459 
14 
0.26 (0.04-1.87) 0.15 1.22 (0.72-2.08) 0.46  
1961 
39 
 
183 
4 
 
470 
14 
1.10 (0.41-2.96) 0.85 1.55 (0.91-2.64) 0.10 
Raf-1338  
negative expression  
positive expression  
 
1390 
641 
 
117 
37 
 
352 
120 
0.68 (0.47-0.98) 0.04 0.74 (0.60-0.91) 0.004  
1407 
592 
 
149 
37 
 
376 
104 
0.58 (0.41-0.83) 0.003 0.64 (0.52-0.80) <0.001 
p44/42 MAPK202/204  
negative expression  
positive expression 
 
1103 
942 
 
93 
62 
 
286 
188 
0.77 (0.56-1.06) 0.11 0.75 (0.62-0.90) 0.002  
1146 
864 
 
124 
63 
 
304 
181 
0.66 (0.49-0.89) 0.006 0.77 (0.64-0.92) 0.004 
IKK alpha and Raf-1338 
both negative 
one positive 
both positive 
 
570 
590 
346 
 
48 
46 
18 
 
137 
132 
58 
0.81 (0.63-1.04) 0.18 0.85 (0.73-0.98) 0.05  
584 
568 
322 
 
67 
56 
19 
 
179 
122 
58 
0.74 (0.59-0.93) 0.03 0.73 (0.63-0.84) <0.001 
IKK alpha, Raf-1338 and ER167 
all negative 
one or two positive 
all positive 
 
167 
1027 
271 
 
15 
80 
13 
 
41 
229 
49 
0.73 (0.51-1.03) 0.17 0.75 (0.70-1.04) 0.27  
172 
1010 
257 
 
22 
98 
16 
 
63 
242 
44 
0.70 (0.51-0.95) 0.08 0.64 (0.52-0.77) <0.001 
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Table 4. Multivariate analysis of associations between biomarkers, clinicopathological characteristics, and RFS at 2.5 and 10 
years in postmenopausal HRec-positive early breast cancer patients by treatment 
HR = Hazard Ratio; CI = Confidence interval; -- = not included in analysis. 
*
Multivariate cox regression survival analysis using a backward conditional 
elimination model and a statistical significance threshold of p<0.01 was performed to identify independent prognostic biomarkers. All statistical tests were two-
sided. 
 
 
Characteristics 
And 
Biomarkers 
All Patients (n=4444) Exemestane Only (n=2240) Tamoxifen followed by Exemestane (n=2204) 
Relapse-free survival at 2.5yrs 
(n=2827) 
Relapse-free survival at 10yrs 
(n=1963) 
Relapse-free survival at 2.5yrs 
(n=1429) 
Relapse-free survival at 10yrs 
(n=980) 
Relapse-free survival at 2.5yrs 
(n=1398) 
Relapse-free survival at 10yrs 
(n=983) 
HR (95% CI) p value* HR (95% CI) p value* HR (95% CI) p value* HR (95% CI) p value* HR (95% CI) p value* HR (95% CI) p value* 
Age  
<50/50-59/60-69/>70 
1.43 (1.23-1.67) <0.001 1.34 (1 20-1.50) <0.001 1.41 (1.11-1.78) 0.004 1.38 (1.18-1.62) <0.001 1.48 (1.20-1.83) <0.001 1.30 (1.11-1.52) 0.001 
Grade  
1/2/3/4 
1.24 (1.04-1.48) 0.02 1.14 (1.01-1.29) 0.04 1.32 (1.01-1.75) 0.04 1.10 (0.92-1.31) 0.28 1.12 (0.90-1.40) 0.32 1.16 (0.97-1.37) 0.10 
Nodal Status  
absent/present 
1.78 (1.34-2.36) <0.001 1.39 (1.08-1.79) 0.01 2.02 (1.31-3.11) 0.001 1.36 (0.93-1.98) 0 12 1.65 (1.14-2.38) 0.008 1.26 (0.87-1.83) 0.22 
Size  
<20mm/>20mm 
1.54 (1.18-2.02) 0.002 1.70 (1.42-2.06) <0.001 1.75 (1.16-2.64) 0.008 1.82 (1.37-2.40) <0.001 1.44 (1.01-2.06) 0.04 1.61 (1.23-2.11) 0.001 
PR status  
absent/present 
1.13 (0.94-1.36) 0.20 1.17 (1.00-1.38) 0.05 1.33 (1.02-1.72) 0.04 1.46 (1.16-1.85) 0.001 0.96 (0.74-1.25) 0.78 0.98 (0.79-1.22) 0.86 
HER2 status 
absent/present 
- - 1.39 (1.15-1.62) 0.001 - - 1.35 (1.04-1.79) 0.02 - - 1.40 (1.06-1.85) 0.02 
Ki67 status  
Low/High 
1.87 (1.44-2.42) <0.001 1.33 (1.09-1.62) 0.006 1.96 (1.32-2.92) 0.001 1.37 (1.04-1.79) 0.03 1.78 (1.27-2.50) 0.001 1.32 (1.00-1.73) 0.05 
phospho ER167  
negative/positive  
0.88 (0.67-1.16) 0.35 0.79 (0.65-0.96) 0.02 0.78 (0.52-1.17) 0.23 0.99 (0.74-1.32) 0.92 1.00 (0.69-1.45) 0.99 0.65 (0.50-0.85) 0.002 
IKK alpha  
absent/present  
- - 0.91 (0.76-1.14) 0.34 - - 1.09 (0.83-1.42) 0.55 - - 0.81 (0.63-1.06) 0.11 
Raf-1338 (n=4030)  
negative/positive 
0.71 (0.52-0.97) 0.03 0.85 (0.65-1.12) 0.26 0.72 (0.46-1.14) 0.16 1.01 (0.68-1.49) 0.98 0.81 (0.51-1.29) 0.37 0.66 (0.50-0.98) 0.04 
p44/42 MAPK202/204  
negative/positive 
0.92 (0.70-1.20) 0.53 0.92 (0.76-1.13) 0.45 1.21 (0.81-1.81) 0.36 0.90 (0.70-1.19) 0.46 0.70 (0.49-1.01) 0.06 0.98 (0.74-1.30) 0.90 
IKK alpha and Raf-1338  
both negative/one 
positive/both positive 
0.82 (0.68-0.99) 0.38 0.89 (0.77-1.04) 0.13 0.79 (0.60-1.05) 0.11 1.03 (0.83-1.27) 0.80 0.81 (0.63-1.05) 0.11 0.76 (0.62-0.93) 0.008 
IKK alpha, Raf-1338 and ER167  
all negative/one or two 
positive/all positive 
- - 0.81 (0.68-0.96) 0.01 - - 0.97 (0.76-1.24) 0.83 - - 0.67 (0.54-0.85) 0.001 
